- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Blueprint Medicines Corp (BPMC)
Blueprint Medicines Corp stock price live, this page displays NASDAQ BPMC stock exchange data. View the BPMC premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Blueprint Medicines Corp real time stock price chart below.
What Is the Blueprint Medicines Corp Stock Price Today?
The Blueprint Medicines Corp stock price today is 129.46.
What Is the Stock Symbol for Blueprint Medicines Corp?
The stock symbol for Blueprint Medicines Corp is ""BPMC.""
What Stock Exchange Does Blueprint Medicines Corp Trade On?
Blueprint Medicines Corp is listed and trades on the NASDAQ stock exchange.
Is Blueprint Medicines Corp a Good Stock to Buy?
Determining whether Blueprint Medicines Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BPMC quote. (ISIN: US09627Y1091)
What Is the Blueprint Medicines Corp Stock Price Today?
The Blueprint Medicines Corp stock price today is 129.46.
What Is the Stock Symbol for Blueprint Medicines Corp?
The stock symbol for Blueprint Medicines Corp is ""BPMC.""
What Stock Exchange Does Blueprint Medicines Corp Trade On?
Blueprint Medicines Corp is listed and trades on the NASDAQ stock exchange.
Is Blueprint Medicines Corp a Good Stock to Buy?
Determining whether Blueprint Medicines Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BPMC quote. (ISIN: US09627Y1091)
129.46
+0.18(+0.14%)
Real-time Data·
Fair Value
An estimate of a Blueprint Medicines Corp's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
129.30
129.55
52 wk Range
73.04
129.65
Showing Blueprint Medicines Corp historical data. For real-time data please try another search
Fair Value
An estimate of a Blueprint Medicines Corp's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
129.30129.55
52 wk Range
73.04129.65
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BPMC Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Blueprint Medicines Corp's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Currently not supported.
- Form 8K Blueprint Medicines Corp For: 18 July
- Investing.com
- Form 8K Blueprint Medicines Corp For: 20 June
- Investing.com
- Form 8K Blueprint Medicines Corp For: 18 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Blueprint Medicines Corp Company Profile
Blueprint Medicines Corporation operates as a global biopharmaceutical company that develops medicines for genomically defined cancers, blood disorders, and allergy/inflammation in the United States and internationally. The company develops AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company develops BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. Blueprint Medicines Corporation was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. The company was incorporated in 2008 and is based in Cambridge, Massachusetts. As of July 18, 2025, Blueprint Medicines Corporation operates as a subsidiary of Sanofi.
Blueprint Medicines Corp SWOT Analysis
Ayvakit's Ascendance | Blueprint's flagship drug Ayvakit drives impressive revenue growth, with projections reaching $2 billion annually by 2030 and potential peak revenue exceeding $4 billion |
Pipeline Promise | Explore Blueprint's diverse pipeline, including BLU-808 for allergic conditions and Elenestinib for indolent systemic mastocytosis, poised to expand market reach |
Financial Trajectory | Analysts expect profitability by late 2026, with current strong cash position of $899.8 million supporting ongoing R&D efforts. Price targets range from $105 to $140 |
Sanofi Synergy | Delve into the implications of Sanofi's acquisition, potentially accelerating Blueprint's growth in precision medicine while navigating integration challenges |
Blueprint Medicines Corp Earnings Call Summary for Q1/2025
- Q1 2025 EPS beat expectations at $0.01 vs -$0.49 forecast; revenue missed at $149.41M vs $156.83M expected
- Full-year revenue guidance raised to $700-$720M; AYVAKIT sales grew 61% YoY
- Stock rose 1.69% pre-market to $91.01; company targets $2B in AYVAKIT revenue by 2030
- CEO Kate Havilland: 'We are exactly where we want to be'; 20% US patient penetration could yield $2B annual revenue
- Challenges include revenue miss, potential market saturation, and intense sector competition
Last Updated: 01/05/2025, 14:28
Read Full TranscriptCompare BPMC to Peers and Sector
Metrics to compare | BPMC | Peers Peers - average of corresponding metrics from companies closely matching BPMC: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBPMCPeersSector |
|---|---|---|---|---|
P/E Ratio | −53.8x | 0.0x | −0.6x | |
PEG Ratio | −1.12 | 0.00 | 0.00 | |
Price/Book | 24.5x | 0.0x | 2.6x | |
Price / LTM Sales | 14.9x | 0.0x | 3.3x | |
Upside (Analyst Target) | −0.4% | 0.0% | 38.7% | |
Fair Value Upside | Unlock | 0.0% | 5.1% | Unlock |
Earnings
Latest Release
Jul 30, 2025
EPS / Forecast
-- / -0.443
Revenue / Forecast
-- / 171.02M
People Also Watch
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.